ArticleJournal of inflammation research2025
Prognostic Value of Inflammatory and Nutritional Markers in Advanced Esophageal Squamous Cell Carcinoma Treated with Immunotherapy: A Retrospective Cohort Study.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate the nutritional, immune, and inflammatory status of esophageal squamous cell carcinoma (ESCC) patients before immunotherapy using blood-based biomarkers, and to develop and validate competing-risk nomogram models to predict overall survival (OS) and progression-free survival (PFS). Patients and Methods: This retrospective study enrolled 300 ESCC patients who received immunotherapy at the First Affiliated Hospital of Zhengzhou University between January 2021 and December 2023, and randomly assigned them to a primary cohort (210 cases) and a validation cohort (90 cases) at a 7:3 ratio. We screened prognostic factors using least absolute shrinkage and selection operator (LASSO) regression coupled with univariate and multivariate Cox regression analyses to construct a nomogram prediction model. Model validation was performed using the following approaches: (1) Calibration curves were employed to evaluate the agreement between predicted and observed outcomes; (2) Discrimination was assessed through the index of concordance (C-index), time-dependent receiver operating characteristic (ROC) curves, and time-dependent area under the curve (AUC); (3) Clinical utility and predictive accuracy were further assessed using net reclassification improvement (NRI), integrated discrimination improvement (IDI), and decision curve analysis (DCA). Furthermore, the performance of the proposed nomogram was systematically compared with the conventional tumor-node-metastasis (TNM) staging system and another published prediction model. Results: Through comprehensive multivariate OS analysis conducted in the primary cohort, we established an innovative prognostic nomogram combining systemic immunoinflammatory index (SII) and prognostic nutritional index (PNI). Compared with TNM staging, our model demonstrated strong accuracy, discriminative ability, and clinical utility in the primary and validation cohorts. Conclusion: This research confirms the prognostic value of SII and PNI in ESCC patients undergoing anti-PD-1 immunotherapy. Given their significant correlation with clinical outcomes, these biomarkers show potential for pretreatment risk assessment in immunotherapy candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.